{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T17:42:26Z","timestamp":1795023746232,"version":"4.10.2"},"reference-count":303,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,4]]},"DOI":"10.1093\/rheumatology\/keaf522","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T11:02:11Z","timestamp":1763118131000},"source":"Crossref","is-referenced-by-count":16,"title":["The 2025 British Society for Rheumatology guideline for the prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs"],"prefix":"10.1093","volume":"65","author":[{"given":"Katie","family":"Bechman","sequence":"first","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyang","family":"Song","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0121-4919","authenticated-orcid":false,"given":"Abhishek","family":"Abhishek","sequence":"additional","affiliation":[{"name":"Academic Rheumatology, City Hospital Nottingham, The University of Nottingham , Nottingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5560-6603","authenticated-orcid":false,"given":"Maryam","family":"Adas","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tameside and Glossop Integrated Care NHS Foundation Trust , Ashton-under-Lyme,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1527-6011","authenticated-orcid":false,"given":"Lisa","family":"Bray","sequence":"additional","affiliation":[{"name":"Department of Paediatric Rheumatology, St Richard\u2019s Hospital , Chichester,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Davidson","sequence":"additional","affiliation":[{"name":"Modality LLP, Community Rheumatology , Birmingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samundeeswari","family":"Deepak","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Nottingham Children\u2019s Hospital, Nottingham University Hospitals NHS Trust , Nottingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinalini","family":"Dey","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope","family":"De Vere","sequence":"additional","affiliation":[{"name":"Medical Education (Rheumatology and Respiratory), Boehringer Ingelheim Ltd , Bracknell,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmandeep","family":"Dhillon","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, New Cross Hospital, Royal Wolverhampton NHS Trust , Wolverhampton,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Faithfull","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Birmingham Children\u2019s Hospital , Birmingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Foulkes","sequence":"additional","affiliation":[{"name":"Department of Dermatopharmacology, Salford Royal NHS Foundation Trust , Salford,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gibson","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8970-4116","authenticated-orcid":false,"given":"Nicola","family":"Gullick","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospitals Coventry & Warwickshire , Coventry,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Hartley","sequence":"additional","affiliation":[{"name":"Department of Paediatric Rheumatology, Newcastle upon Tyne Hospitals NHS Foundation Trust , Newcastle,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Heaton","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Stepping Hill Hospital, Stockport NHS Foundation Trust , Stockport,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9958-3909","authenticated-orcid":false,"given":"Samantha","family":"Hider","sequence":"additional","affiliation":[{"name":"School of Medicine, Keele University , Keele,","place":["UK"]},{"name":"Department of Rheumatology, Midlands Partnership University NHS Foundation Trust , Stoke-on-Trent,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Holmes","sequence":"additional","affiliation":[{"name":"Expert by Experience, Arthritis UK Research Partner , Doncaster,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Jones","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Powys Teaching Health Board , Brecon, Powys,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhila","family":"Kavirayani","sequence":"additional","affiliation":[{"name":"Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Foundation Trust , Oxford,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameena","family":"Khalid","sequence":"additional","affiliation":[{"name":"Rheumatology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals , Sheffield,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Kyle","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, North Devon District Hospital, Royal Devon University , Devon,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2483-5873","authenticated-orcid":false,"given":"Sarah L","family":"Mackie","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds , Leeds,","place":["UK"]},{"name":"Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust , Leeds,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madura","family":"Adikari","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Rotherham General Hospital, Rotherham NHS Foundation Trust , Rotherham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Nash","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Sheffield Children\u2019s NHS Foundation Trust , Sheffield,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9957-0446","authenticated-orcid":false,"given":"Katarzyna","family":"Nowak","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Belfast Health and Social Care Trust , Belfast,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Parsons","sequence":"additional","affiliation":[{"name":"Expert by Experience , Richmond,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Patel","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhra","family":"Raghuvanshi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Wrexham Maelor Hospital, Betsi Cadawaladr University Hospital , Wrexham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8962-4404","authenticated-orcid":false,"given":"John A","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Department of Inflammation and Ageing, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham , Birmingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Rose-Parfitt","sequence":"additional","affiliation":[{"name":"Southmead Hospital, North Bristol NHS Trust , Bristol,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2202-6266","authenticated-orcid":false,"given":"Sarah","family":"Ryan","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Midlands Partnership University NHS Foundation Trust , Stoke-on-Trent,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanaa","family":"Said","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, State University of Zanzibar , Tunguu, Zanzibar,","place":["Tanzania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4212-5875","authenticated-orcid":false,"given":"Pratyasha","family":"Saha","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Norfolk and Norwich University Hospital , Norfolk,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Scott","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Stepping Hill Hospital, Stockport NHS Foundation Trust , Stockport,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Shivamurthy","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Evelina London Children\u2019s Hospital, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Yin","family":"Tan","sequence":"additional","affiliation":[{"name":"Rheumatology Department, NHS Tayside , Dundee,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8781-1268","authenticated-orcid":false,"given":"Helen","family":"Twohig","sequence":"additional","affiliation":[{"name":"School of Medicine, Keele University , Keele,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishore","family":"Warrier","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Nottingham Children\u2019s Hospital, Nottingham University Hospitals NHS Trust , Nottingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Wood","sequence":"additional","affiliation":[{"name":"Brannam Medical Centre , Barnstaple,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Zabate","sequence":"additional","affiliation":[{"name":"Rheumatic Diseases Unit, Western General Hospital NHS Lothian , Edinburgh,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0077-6074","authenticated-orcid":false,"given":"Benjamin","family":"Zuckerman","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1230-2781","authenticated-orcid":false,"given":"James","family":"Galloway","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2108-3393","authenticated-orcid":false,"given":"Louise","family":"Mercer","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Stepping Hill Hospital, Stockport NHS Foundation Trust , Stockport,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"British Society for Rheumatology Guidelines Steering Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"2026022606015088700_keaf522-B1","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/rheumatology\/keh199","article-title":"Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis","volume":"43","author":"Nell","year":"2004","journal-title":"Rheumatology"},{"key":"2026022606015088700_keaf522-B2","first-page":"iii114","article-title":"Treating rheumatoid arthritis to target: outcomes and predictors in early rheumatoid arthritis patients treated with adalimumab plus methotrexate, methotrexate alone or methotrexate plus subsequent adalimumab","volume":"51","author":"Smolen","year":"2012","journal-title":"Rheumatology (United Kingdom)."},{"key":"2026022606015088700_keaf522-B3","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1136\/annrheumdis-2011-200274","article-title":"A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry","volume":"71","author":"Schipper","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2026022606015088700_keaf522-B4","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/rheumatology\/kew479","article-title":"BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs","volume":"56","author":"Ledingham","year":"2017","journal-title":"Rheumatology"},{"key":"2026022606015088700_keaf522-B5","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/rheumatology\/keac558","article-title":"British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids","volume":"62","author":"Russell","year":"2023","journal-title":"Rheumatology"},{"key":"2026022606015088700_keaf522-B6","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1093\/rheumatology\/key208","article-title":"The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis","volume":"58","author":"Holroyd","year":"2019","journal-title":"Rheumatology"},{"key":"2026022606015088700_keaf522-B7","author":"British Society for Rheumatology"},{"key":"2026022606015088700_keaf522-B8"},{"key":"2026022606015088700_keaf522-B9","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Intern Med"},{"key":"2026022606015088700_keaf522-B10","doi-asserted-by":"crossref","first-page":"R189","DOI":"10.1186\/ar3517","article-title":"Primary care physicians\u2019 perspectives towards managing rheumatoid arthritis: room for improvement","volume":"13","author":"Garneau","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2026022606015088700_keaf522-B11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/art.21077","article-title":"Gaps in care for rheumatoid arthritis: a population study","volume":"53","author":"Lacaille","year":"2005","journal-title":"Arthritis Care Res"},{"key":"2026022606015088700_keaf522-B12","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/acr2.11406","article-title":"Provider specialty and the use of disease-modifying antirheumatic drugs for rheumatoid arthritis among older adults in the 2005-2016 National Ambulatory Medical Care Survey","volume":"4","author":"Lee","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"2026022606015088700_keaf522-B13","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/ard.2009.108332","article-title":"Repair of joint erosions in rheumatoid arthritis: prevalence and patient characteristics in a large inception cohort","volume":"69","author":"Van Der Linden","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2026022606015088700_keaf522-B14","doi-asserted-by":"crossref","first-page":"152041","DOI":"10.1016\/j.semarthrit.2022.152041","article-title":"Shared decision making in rheumatology: a scoping review","volume":"56","author":"Morrison","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2026022606015088700_keaf522-B15","author":"NICE","year":"2020"},{"key":"2026022606015088700_keaf522-B16","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0003-4967(24)43387-6","article-title":"Effect of patient education on adherence to drug treatment for rheumatoid arthritis: a randomised controlled trial","volume":"60","author":"Hill","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"2026022606015088700_keaf522-B17","first-page":"28","article-title":"Evaluation of the efficacy of an educational program for rheumatoid arthritis patients","volume":"27","author":"Neto","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"2026022606015088700_keaf522-B18","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s00296-005-0071-6","article-title":"Health-related quality of life in rheumatoid arthritis: therapeutic education plus pharmacological treatment versus pharmacological treatment only","volume":"26","author":"N\u00fa\u00f1ez","year":"2006","journal-title":"Rheumatol Int"},{"key":"2026022606015088700_keaf522-B19","author":"Riemsma"},{"key":"2026022606015088700_keaf522-B20","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/annrheumdis-2014-206807","article-title":"EULAR recommendations for patient education for people with inflammatory arthritis","volume":"74","author":"Zangi","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2026022606015088700_keaf522-B21","doi-asserted-by":"crossref","first-page":"152575","DOI":"10.1016\/j.semarthrit.2024.152575","article-title":"Information and communication technology-based patient education for autoimmune inflammatory rheumatic diseases: a scoping review","volume":"69","author":"Yoon","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2026022606015088700_keaf522-B22","first-page":"290","volume":"7"},{"key":"2026022606015088700_keaf522-B23","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/rheumatology\/keh175","article-title":"User perspectives of transitional care for adolescents with juvenile idiopathic arthritis","volume":"43","author":"Shaw","year":"2004","journal-title":"Rheumatology"},{"key":"2026022606015088700_keaf522-B24","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/annrheumdis-2016-210112","article-title":"EULAR\/PReS standards and recommendations for the transitional care of young people with juvenile-onset rheumatic diseases","volume":"76","author":"Foster","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026022606015088700_keaf522-B25","author":"NICE","year":"2016"},{"key":"2026022606015088700_keaf522-B26","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/rheumatology\/keac559","article-title":"British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: comorbidity medications used in rheumatology practice","volume":"62","author":"Schreiber","year":"2023","journal-title":"Rheumatology"},{"key":"2026022606015088700_keaf522-B27","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nrrheum.2015.112","article-title":"Cardiovascular comorbidity in rheumatic diseases","volume":"11","author":"Nurmohamed","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"2026022606015088700_keaf522-B28","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/rheumatology\/kem169","article-title":"Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis","volume":"46","author":"Panoulas","year":"2007","journal-title":"Rheumatology"},{"key":"2026022606015088700_keaf522-B29","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1007\/s10067-019-04579-1","article-title":"Comorbidity burden and clinical characteristics of patients with difficult-to-control rheumatoid arthritis","volume":"38","author":"Batko","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2026022606015088700_keaf522-B30","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/RHU.0000000000000736","article-title":"Initiation of disease-modifying therapies in rheumatoid arthritis is associated with changes in blood pressure","volume":"24","author":"Baker","year":"2018","journal-title":"J Clin Rheumatol"},{"key":"2026022606015088700_keaf522-B31","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/17512433.2022.2092470","article-title":"Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis","volume":"15","author":"Gelder","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2026022606015088700_keaf522-B32","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1001\/jama.282.22.2131","article-title":"Elevated C-reactive protein levels in overweight and obese adults","volume":"282","author":"Visser","year":"1999","journal-title":"JAMA"},{"key":"2026022606015088700_keaf522-B33","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/rheumatology\/key066","article-title":"The association of obesity with disease activity, functional ability and quality of life in early rheumatoid arthritis: data from the Early Rheumatoid Arthritis Study\/Early Rheumatoid Arthritis Network UK prospective cohorts","volume":"57","author":"Nikiphorou","year":"2018","journal-title":"Rheumatology"},{"key":"2026022606015088700_keaf522-B34"},{"key":"2026022606015088700_keaf522-B35","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/art.41934","article-title":"American college of rheumatology white paper on antimalarial cardiac toxicity","volume":"73","author":"Desmarais","year":"2021","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"2026022606015088700_keaf522-B36","year":"2025"},{"key":"2026022606015088700_keaf522-B37","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/sarh.2000.16641","article-title":"Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis","volume":"30","author":"Schiff","year":"2000","journal-title":"Seminars Arthritis Rheum"},{"key":"2026022606015088700_keaf522-B38","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejmech.2018.09.027","article-title":"Side effects of methotrexate therapy for rheumatoid arthritis: a systematic review","volume":"158","author":"Wang","year":"2018","journal-title":"Eur J Med Chem"},{"key":"2026022606015088700_keaf522-B39","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/annrheumdis-2013-204223","article-title":"Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)","volume":"73","author":"Dougados","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2026022606015088700_keaf522-B40","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1046\/j.1600-6143.2003.00372.x","article-title":"New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis","volume":"4","author":"Heisel","year":"2004","journal-title":"Am J Transplant"},{"key":"2026022606015088700_keaf522-B41","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S1053-2498(98)00060-6","article-title":"A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus","volume":"18","author":"Taylor","year":"1999","journal-title":"J Heart Lung Transplant"},{"key":"2026022606015088700_keaf522-B42","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3390\/transplantology3020020","article-title":"Dyslipidemia in renal transplant recipients","volume":"3","author":"Chmielnicka","year":"2022","journal-title":"Transplantology"},{"key":"2026022606015088700_keaf522-B43","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/2168479017728987","article-title":"Comparison of serious adverse event profiles among antirheumatic agents using Japanese adverse drug event report database","volume":"52","year":"2018","journal-title":"Ther Innov Regul Sci"},{"key":"2026022606015088700_keaf522-B44","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/art.24476","article-title":"Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada","volume":"61","author":"Brassard","year":"2009","journal-title":"Arthritis Care Res"},{"key":"2026022606015088700_keaf522-B45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2012.12.966","article-title":"Association between traditional systemic antipsoriatic drugs and tuberculosis risk in patients with psoriasis with or without psoriatic arthritis: results of a nationwide cohort study from Taiwan","volume":"69","author":"Chen","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2026022606015088700_keaf522-B46","author":"NICE","year":"2024"},{"key":"2026022606015088700_keaf522-B47","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1183\/09031936.00114810","article-title":"Interferon-\u03b3 release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis","volume":"37","author":"Sester","year":"2011","journal-title":"Eur Respir J"},{"key":"2026022606015088700_keaf522-B48","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.4769","volume":"7","author":"Ayers","year":"2024","journal-title":"JAMA Network Open"},{"key":"2026022606015088700_keaf522-B49","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/ard.2007.070789","article-title":"Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon \u03b3 assay","volume":"67","author":"Matulis","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2026022606015088700_keaf522-B50","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10067-014-2817-6","article-title":"Screening of latent tuberculosis infection by interferon-\u03b3 release assays in rheumatic patients: a systemic review and meta-analysis","volume":"35","author":"Ruan","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2026022606015088700_keaf522-B51","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S1473-3099(18)30355-4","article-title":"Prognostic value of interferon-\u03b3 release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study","volume":"18","author":"Abubakar","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2026022606015088700_keaf522-B52","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/art.34382","article-title":"Interferon-\u03b3 release assay versus tuberculin skin test prior to treatment with golimumab, a human anti\u2013tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis","volume":"64","author":"Hsia","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2026022606015088700_keaf522-B53","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026022606015088700_keaf522-B54","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/ard.2008.101857","article-title":"Comparison of interferon \u03b3 release assays and conventional screening tests before tumour necrosis factor \u03b1 blockade in patients with inflammatory arthritis","volume":"69","author":"Martin","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2026022606015088700_keaf522-B55","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00296-012-2641-8","article-title":"Screening for latent TB in patients with rheumatic disorders prior to biologic agents in a \u2018high-risk\u2019 TB population: comparison of two interferon gamma release assays","volume":"34","author":"Melath","year":"2014","journal-title":"Rheumatol Int"},{"key":"2026022606015088700_keaf522-B56","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3109\/14397595.2016.1149267","article-title":"A comparative analysis of two interferon-\u03b3 releasing assays to detect past tuberculosis infections in Japanese rheumatoid arthritis patients","volume":"26","author":"Iwagaitsu","year":"2016","journal-title":"Modern Rheumatol"},{"key":"2026022606015088700_keaf522-B57","author":"UK Health Security Agency","year":"2024"},{"key":"2026022606015088700_keaf522-B58","author":"NICE","year":"2013"},{"key":"2026022606015088700_keaf522-B59","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.gastro.2024.11.008","article-title":"AGA Clinical practice guideline on the prevention and treatment of hepatitis B virus reactivation in at-risk individuals","volume":"168","year":"2025","journal-title":"Gastroenterology"},{"key":"2026022606015088700_keaf522-B60","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/jama.2018.3795","article-title":"Chronic Hepatitis B Infection","volume":"319","author":"Tang","year":"2018","journal-title":"JAMA"},{"key":"2026022606015088700_keaf522-B61","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.1840180605","article-title":"Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B","volume":"18","author":"Fong","year":"1993","journal-title":"Hepatology"},{"key":"2026022606015088700_keaf522-B62","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/nm1096-1104","article-title":"The hepatitis B virus persists for decades after patients\u2019 recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response","volume":"2","author":"Rehermann B, Ferrari C, Pasquinelli C, Chisari FV.","year":"1996","journal-title":"Nat Med"},{"key":"2026022606015088700_keaf522-B63","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1200\/JCO.2012.48.5938","article-title":"Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B","volume":"31","author":"Huang","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026022606015088700_keaf522-B64","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1002\/hep.26718","article-title":"Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study","volume":"59","author":"Hsu","year":"2014","journal-title":"Hepatology"},{"key":"2026022606015088700_keaf522-B65","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/acr.23346","article-title":"Risk of hepatitis B virus reactivation in patients with inflammatory arthritis receiving disease-modifying antirheumatic drugs: a systematic review and meta-analysis","volume":"70","author":"Lin","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2026022606015088700_keaf522-B66","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","article-title":"Natural history of hepatitis C","volume":"61","author":"Westbrook","year":"2014","journal-title":"J Hepatol"},{"key":"2026022606015088700_keaf522-B67","doi-asserted-by":"crossref","first-page":"e2245424","DOI":"10.1001\/jamanetworkopen.2022.45424","article-title":"Characteristics and treatment rate of patients with hepatitis C virus infection in the direct-acting antiviral era and during the COVID-19 pandemic in the United States","volume":"5","author":"Nguyen","year":"2022","journal-title":"JAMA Network Open"},{"key":"2026022606015088700_keaf522-B68","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/rheumatology\/ker190","article-title":"Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review","volume":"50","author":"Brunasso","year":"2011","journal-title":"Rheumatology"},{"key":"2026022606015088700_keaf522-B69","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/RHU.0000000000000536","article-title":"Retrospective study of patients on etanercept therapy for rheumatic diseases in patients with chronic hepatitis C virus","volume":"23","author":"Gandhi","year":"2017","journal-title":"J Clin Rheumatol"},{"key":"2026022606015088700_keaf522-B70","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10067-013-2378-0","article-title":"Long-term safety of anti-TNF-\u03b1 in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients","volume":"33","author":"Costa","year":"2014","journal-title":"Clin Rheumatol"},{"key":"2026022606015088700_keaf522-B71","author":"Public Health England","year":"2020"},{"key":"2026022606015088700_keaf522-B72","author":"NICE","year":"2016"},{"key":"2026022606015088700_keaf522-B73","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1136\/ard.2009.117200","article-title":"European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies","volume":"69","author":"Mosca","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2026022606015088700_keaf522-B74","author":"UK Health Security Agency","year":"2024"},{"key":"2026022606015088700_keaf522-B75"},{"key":"2026022606015088700_keaf522-B76"},{"key":"2026022606015088700_keaf522-B77","author":"UK Health Security Agency"},{"key":"2026022606015088700_keaf522-B78"},{"key":"2026022606015088700_keaf522-B79","author":"UK Health Security Agency"},{"key":"2026022606015088700_keaf522-B80"},{"key":"2026022606015088700_keaf522-B81","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/annrheumdis-2024-eular.1621","article-title":"OP0140 timeframe for initiating methotrexate and vaccination protection against pneumococcus in rheumatoid arthritis: the Vacimra study","volume":"83","author":"Morel","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026022606015088700_keaf522-B82","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jinf.2021.12.044","article-title":"Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups","volume":"84","author":"Whitaker","year":"2022","journal-title":"J Infect"},{"key":"2026022606015088700_keaf522-B83","author":"Department of Health & Social Care","year":"2023"},{"key":"2026022606015088700_keaf522-B84"},{"key":"2026022606015088700_keaf522-B85"},{"key":"2026022606015088700_keaf522-B86","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"New Engl J Med"},{"key":"2026022606015088700_keaf522-B87","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"New Engl J Med"},{"key":"2026022606015088700_keaf522-B88","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2026022606015088700_keaf522-B89","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/annrheumdis-2022-222574","article-title":"EULAR\/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021","volume":"82","author":"Jansen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026022606015088700_keaf522-B90","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1001\/jama.2013.6768","article-title":"Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial","volume":"309","author":"Heijstek","year":"2013","journal-title":"JAMA"},{"key":"2026022606015088700_keaf522-B91","first-page":"791","article-title":"Immune response and tolerability of varicella vaccine in children and adolescents with systemic lupus erythematosus previously exposed to varicella-zoster virus","volume":"30","author":"Barbosa","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2026022606015088700_keaf522-B92","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1016\/j.vaccine.2017.04.015","article-title":"Varicella vaccination elicits a humoral and cellular response in children with rheumatic diseases using immune suppressive treatment","volume":"35","author":"Groot","year":"2017","journal-title":"Vaccine"},{"key":"2026022606015088700_keaf522-B93"},{"key":"2026022606015088700_keaf522-B94","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1093\/rheumatology\/keae305","article-title":"Pneumococcal vaccine uptake in patients with inflammatory arthritis: a single centre cohort study","volume":"64","author":"Nagra","year":"2025","journal-title":"Rheumatology (Oxford, England)"},{"key":"2026022606015088700_keaf522-B95","first-page":"962","author":"Nakafero"},{"key":"2026022606015088700_keaf522-B96","doi-asserted-by":"crossref","first-page":"SI143","DOI":"10.1093\/rheumatology\/keac249","article-title":"Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey","volume":"61","author":"Rider","year":"2022","journal-title":"Rheumatology"},{"key":"2026022606015088700_keaf522-B97","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/rheumatology\/kex519","article-title":"Managing varicella zoster virus contact and infection in patients on anti-rheumatic therapy","volume":"57","author":"Cates","year":"2018","journal-title":"Rheumatology"},{"key":"2026022606015088700_keaf522-B98","doi-asserted-by":"crossref","first-page":"e00265","DOI":"10.1128\/JCM.00265-20","article-title":"Qualitative variation among commercial immunoassays for detection of measles-specific IgG","volume":"58","author":"Latner","year":"2020","journal-title":"J Clin Microbiol"},{"key":"2026022606015088700_keaf522-B99","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.3390\/vaccines10111859","article-title":"Seroprevalence of measles antibodies in a highly MMR-vaccinated population","volume":"10","author":"Quach","year":"2022","journal-title":"Vaccines"},{"key":"2026022606015088700_keaf522-B100","doi-asserted-by":"crossref","first-page":"ofy244","DOI":"10.1093\/ofid\/ofy244","article-title":"Fatal measles virus infection after rituximab-containing chemotherapy in a previously vaccinated patient","volume":"5","author":"Jent","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2026022606015088700_keaf522-B101","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(25)00223-3","article-title":"Haemophagocytic lymphohistiocytosis (HLH) secondary to measles in an adult with a loss of post-vaccination humoral immunity following rituximab","author":"Notghi","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026022606015088700_keaf522-B102","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1136\/annrheumdis-2018-213222","article-title":"Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026022606015088700_keaf522-B103","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1136\/annrheumdis-2017-211128","article-title":"Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial","volume":"76","author":"Park","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026022606015088700_keaf522-B104","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/art.42644","article-title":"Effect of the methotrexate discontinuation for 1 versus 2\u2009weeks on vaccine response to seasonal influenza vaccine in rheumatoid arthritis: a noninferiority randomized controlled trial","volume":"77","author":"Park","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"2026022606015088700_keaf522-B105","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/art.42318","article-title":"A multicenter, prospective, randomized, parallel-group trial on the effects of temporary methotrexate discontinuation for one week versus two weeks on seasonal influenza vaccination in patients with rheumatoid arthritis","volume":"75","author":"Park","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2026022606015088700_keaf522-B106","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/annrheumdis-2021-221916","article-title":"Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial","volume":"81","author":"Araujo","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026022606015088700_keaf522-B107","doi-asserted-by":"crossref","first-page":"e755","DOI":"10.1016\/S2665-9913(22)00228-4","article-title":"Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised controlled trials","volume":"4","author":"Skaria","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2026022606015088700_keaf522-B108","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1016\/S2665-9913(23)00298-9","article-title":"Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial","volume":"6","author":"Abhishek","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"2026022606015088700_keaf522-B109","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002203","article-title":"Does an adjustment to the dosing and timing of immunomodulatory drugs alter the immunogenicity of the COVID-19 vaccines in patients with autoimmune and inflammatory rheumatic disease (AIIRD)?","volume":"8","author":"Laster","year":"2022","journal-title":"RMD Open"},{"key":"2026022606015088700_keaf522-B110","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1093\/rheumatology\/kead031","article-title":"COVID-19 mRNA vaccine immunogenicity decay and breakthrough illness in adolescents and young adults with childhood-onset rheumatic diseases","volume":"62","author":"Yeo","year":"2023","journal-title":"Rheumatology (Oxford, England)"},{"key":"2026022606015088700_keaf522-B111","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/rmdopen-2022-002639","article-title":"Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination","volume":"8","author":"Habermann","year":"2022","journal-title":"RMD Open"},{"key":"2026022606015088700_keaf522-B112","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/acr.25045","article-title":"2022 American college of rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases","volume":"75","author":"Bass","year":"2023","journal-title":"Arthritis Care Res"},{"key":"2026022606015088700_keaf522-B113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00296-002-0186-y","article-title":"Methotrexate twice weekly vs once weekly in rheumatoid arthritis: a pilot double-blind, controlled study","volume":"22","author":"Pandya","year":"2002","journal-title":"Rheumatol Int"},{"key":"2026022606015088700_keaf522-B114","author":"Medicines and Healthcare products Regulatory Agency","year":"2020"},{"key":"2026022606015088700_keaf522-B115","author":"NHS England","year":"2024"},{"key":"2026022606015088700_keaf522-B116","author":"British National Formulary (BNF)"},{"key":"2026022606015088700_keaf522-B117","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1093\/rheumatology\/keaf257","article-title":"The safety of low-dose methotrexate for rheumatic diseases: looking beyond blood monitoring","volume":"64","author":"Mackie","year":"2025","journal-title":"Rheumatology"},{"key":"2026022606015088700_keaf522-B118","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/14740338.2024.2338257","article-title":"An observational study of root-cause analysis of medication errors in elderly with methotrexate toxicity","volume":"23","author":"Bisht","year":"2024","journal-title":"Expert Opin Drug Safety"},{"key":"2026022606015088700_keaf522-B119","article-title":"Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis","volume":"2013","author":"Shea B, Swinden MV, Tanjong Ghogomu E","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2026022606015088700_keaf522-B120","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/1756-185X.13442","article-title":"Association between cumulative methotrexate dose, non-invasive scoring system and hepatic fibrosis detected by Fibroscan in rheumatoid arthritis patients receiving methotrexate","volume":"22","author":"Lertnawapan","year":"2019","journal-title":"International Journal of Rheumatic Diseases"},{"key":"2026022606015088700_keaf522-B121","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1007\/s10067-021-05678-8","article-title":"Prevalence of liver fibrosis by Fibroscan in patients on long-term methotrexate therapy for rheumatoid arthritis","volume":"40","author":"Bafna","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2026022606015088700_keaf522-B122","doi-asserted-by":"crossref","first-page":"369","DOI":"10.7326\/M19-3369","article-title":"Adverse effects of low-dose methotrexate","volume":"172","author":"Solomon","year":"2020","journal-title":"Ann Intern Med"},{"key":"2026022606015088700_keaf522-B123","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3899\/jrheum.211281","article-title":"Using fibroscan to assess for the development of liver fibrosis in patients with arthritis on methotrexate: a single-center experience","volume":"49","author":"Darabian","year":"2022","journal-title":"J Rheumatol"},{"key":"2026022606015088700_keaf522-B124","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejim.2019.08.022","article-title":"Methotrexate therapy is not associated with increased liver stiffness and significant liver fibrosis in rheumatoid arthritis patients: a cross-sectional controlled study with real-time two-dimensional shear wave elastography","volume":"69","author":"Erre","year":"2019","journal-title":"Eur J Intern Med"},{"key":"2026022606015088700_keaf522-B125","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.jbspin.2010.02.024","article-title":"Assessment of liver fibrosis by transient elastography in rheumatoid arthritis patients treated with methotrexate","volume":"77","author":"Park","year":"2010","journal-title":"Joint Bone Spine"},{"key":"2026022606015088700_keaf522-B126","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00296-021-04804-8","article-title":"Methotrexate does not increase the risk of liver fibrosis in patients with rheumatoid arthritis: assessment by ultrasound elastography (ARFI-MetRA study)","volume":"41","author":"Feuchtenberger","year":"2021","journal-title":"Rheumatol Int"},{"key":"2026022606015088700_keaf522-B127","article-title":"Evaluation of liver elasticity with shear-wave elastography in juvenile idiopathic arthritis patients receiving methotrexate","volume":"64","author":"\u00c7i\u00e7ek","year":"2022","journal-title":"Pediatr Int"},{"key":"2026022606015088700_keaf522-B128","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1136\/jim-2021-002206","article-title":"Review of existing evidence demonstrates that methotrexate does not cause liver fibrosis","volume":"70","author":"Cheema","year":"2022","journal-title":"J Invest Med"},{"key":"2026022606015088700_keaf522-B129","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/ajd.13546","article-title":"Is methotrexate hepatotoxicity associated with cumulative dose? A systematic review and meta-analysis","volume":"62","author":"Azzam","year":"2021","journal-title":"Australas J Dermatol"},{"key":"2026022606015088700_keaf522-B130","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.3899\/jrheum.090482","article-title":"Monitoring methotrexate toxicity in juvenile idiopathic arthritis","volume":"36","author":"Kocharla","year":"2009","journal-title":"J Rheumatol"},{"key":"2026022606015088700_keaf522-B131","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41584-022-00883-4","article-title":"Busting the myth of methotrexate chronic hepatotoxicity","volume":"19","author":"Di Martino","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2026022606015088700_keaf522-B132","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"2026022606015088700_keaf522-B133","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"2026022606015088700_keaf522-B134","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s40618-022-01755-0","article-title":"Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies","volume":"45","author":"Bellinato","year":"2022","journal-title":"J Endocrinol Invest"},{"key":"2026022606015088700_keaf522-B135","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/hepr.14004","article-title":"New concept in fatty liver diseases","volume":"54","author":"Tokushige","year":"2024","journal-title":"Hepatol Res"},{"key":"2026022606015088700_keaf522-B136","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1155\/1996\/213596","article-title":"Methotrexate hepatotoxicity in psoriatics: report of 104 patients from nova scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up","volume":"10","author":"Malatjalian","year":"1996","journal-title":"Can J Gastroenterol Hepatol"},{"key":"2026022606015088700_keaf522-B137","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1046\/j.1440-1746.2001.02644.x","article-title":"Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury","volume":"16","author":"Langman","year":"2001","journal-title":"J Gastroenterol Hepatol"},{"key":"2026022606015088700_keaf522-B138","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1365-2036.2006.03047.x","article-title":"Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent","volume":"24","author":"Berends","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"2026022606015088700_keaf522-B139","first-page":"1029","article-title":"Prevalence and risk factors for liver fibrosis detected by transient elastography or shear wave elastography in inflammatory arthritis: a systematic review","volume":"35","author":"Rouhi","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2026022606015088700_keaf522-B140","author":"NICE","year":"2022"},{"key":"2026022606015088700_keaf522-B141","author":"NICE","year":"2016"},{"key":"2026022606015088700_keaf522-B142","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1136\/flgastro-2013-100403","article-title":"Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging","volume":"5","author":"Dyson","year":"2014","journal-title":"Frontline Gastroenterol"},{"key":"2026022606015088700_keaf522-B143","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2017-314924","article-title":"Guidelines on the management of abnormal liver blood tests","volume":"67","author":"Newsome","year":"2018","journal-title":"Gut"},{"key":"2026022606015088700_keaf522-B144","author":"NICE","year":"2023"},{"key":"2026022606015088700_keaf522-B145","doi-asserted-by":"crossref","first-page":"100003","DOI":"10.1016\/j.clirex.2020.100003","article-title":"A pragmatic non-invasive assessment of liver fibrosis in patients with psoriasis, rheumatoid arthritis or Crohn\u2019s disease receiving methotrexate therapy","volume":"44S","author":"Cervoni","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2026022606015088700_keaf522-B146","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jhep.2010.04.043","article-title":"Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case\u2013control study","volume":"53","author":"Laharie","year":"2010","journal-title":"J Hepatol"},{"key":"2026022606015088700_keaf522-B147","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/imj.15125","article-title":"Assessment of liver fibrosis markers in people with rheumatoid arthritis on methotrexate","volume":"52","author":"Olsson-White","year":"2022","journal-title":"Intern Med J"},{"key":"2026022606015088700_keaf522-B148","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/14397595.2018.1558760","article-title":"Fibrosis-4 index at diagnosis can predict all-cause mortality in patients with rheumatoid arthritis: a retrospective monocentric study","volume":"30","author":"Kim","year":"2020","journal-title":"Modern Rheumatol"},{"key":"2026022606015088700_keaf522-B149","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1080\/14397595.2018.1542962","article-title":"Validation of the fibrosis-4 (FIB-4) index in the diagnosis of liver disease of rheumatoid arthritis patients treated with methotrexate","volume":"29","author":"Miyata","year":"2019","journal-title":"Modern Rheumatol"},{"key":"2026022606015088700_keaf522-B150","doi-asserted-by":"crossref","first-page":"150","DOI":"10.55563\/clinexprheumatol\/usddjr","article-title":"Risk of liver fibrosis induced by methotrexate and other rheumatoid arthritis medications according to the Fibrosis-4 Index","volume":"40","author":"Avouac","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2026022606015088700_keaf522-B151","doi-asserted-by":"crossref","first-page":"e15390","DOI":"10.1111\/1756-185X.15390","article-title":"Liver fibrosis in inflammatory arthritis patients treated with methotrexate and hydroxychloroquine: a FIB-4 index analysis","volume":"27","author":"Uzun","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"2026022606015088700_keaf522-B152","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.3390\/jcm13071905","article-title":"Repurposing the fibrosis-4 score in rheumatoid arthritis: data from the ESPOIR cohort","volume":"13","author":"Felten","year":"2024","journal-title":"J Clin Med"},{"key":"2026022606015088700_keaf522-B153","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1007\/s10620-014-3494-7","article-title":"The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease","volume":"60","author":"Mansoor","year":"2015","journal-title":"Digest Dis Sci"},{"key":"2026022606015088700_keaf522-B154","doi-asserted-by":"crossref","first-page":"101755","DOI":"10.1016\/j.clinre.2021.101755","article-title":"Non-invasive assessment of fibrosis and steatosis in pediatric non-alcoholic fatty liver disease","volume":"46","author":"Chen","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2026022606015088700_keaf522-B155","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"},{"key":"2026022606015088700_keaf522-B156","first-page":"428","article-title":"Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan\u00ae M\/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study","volume":"55","author":"Oeda","year":"2020","journal-title":"J Gastroenterol 2019"},{"key":"2026022606015088700_keaf522-B157","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026022606015088700_keaf522-B158","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/hepr.13508","article-title":"Diagnostic accuracy of FibroScan-AST score to identify non-alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non-alcoholic fatty liver disease: comparison between M and XL probes","volume":"50","author":"Oeda","year":"2020","journal-title":"Hepatol Res"},{"key":"2026022606015088700_keaf522-B159","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/gut.2006.111302","article-title":"Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease","volume":"56","author":"Fraquelli","year":"2007","journal-title":"Gut"},{"key":"2026022606015088700_keaf522-B160","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/hep.23425","article-title":"Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations","volume":"51","author":"Cast\u00e9ra","year":"2010","journal-title":"Hepatology"},{"key":"2026022606015088700_keaf522-B161","author":"NICE [Internet]","year":"2016"},{"key":"2026022606015088700_keaf522-B162","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.dld.2010.07.008","article-title":"Normal liver stiffness and its determinants in healthy blood donors","volume":"43","author":"Colombo","year":"2011","journal-title":"Digest Liver Dis"},{"key":"2026022606015088700_keaf522-B163","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1478-3231.2009.02172.x","article-title":"What are \u2018true normal\u2019 liver stiffness values using FibroScan\u00ae?: a prospective study in healthy living liver and kidney donors in South Korea","volume":"30","author":"Kim","year":"2010","journal-title":"Liver Int"},{"key":"2026022606015088700_keaf522-B164","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/MPG.0000000000001171","article-title":"Ultrasound elastography is useful for evaluation of liver fibrosis in children\u2014a systematic review","volume":"63","author":"Andersen","year":"2016","journal-title":"Journal of pediatric gastroenterology and nutrition"},{"key":"2026022606015088700_keaf522-B165","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.advms.2023.12.001","article-title":"Liver fibrosis assessment in pediatric population\u2014can ultrasound elastography be an alternative method to liver biopsy? A systematic review","volume":"69","author":"Medy\u0144ska-Prz\u0119czek","year":"2024","journal-title":"Adv Med Sci"},{"key":"2026022606015088700_keaf522-B166","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2217\/pgs.09.155","article-title":"Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications?","volume":"11","author":"Higgs","year":"2010","journal-title":"Pharmacogenomics"},{"key":"2026022606015088700_keaf522-B167","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1038\/sj.onc.1209372","article-title":"Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions","volume":"25","author":"Wang","year":"2006","journal-title":"Oncogene"},{"key":"2026022606015088700_keaf522-B168","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ejhg.2009.10","article-title":"Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain","volume":"17","author":"Gurwitz","year":"2009","journal-title":"Eur J Hum Genet"},{"key":"2026022606015088700_keaf522-B169","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/cpt.1304","article-title":"Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update","volume":"105","author":"Relling","year":"2019","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"2026022606015088700_keaf522-B170","author":"British Oncology Pharmacy Association","year":"2023"},{"key":"2026022606015088700_keaf522-B171","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0002-9343(83)91264-0","article-title":"Pharmacologic actions of 4-aminoquinoline compounds","volume":"75","author":"Mackenzie","year":"1983","journal-title":"Am J Med"},{"key":"2026022606015088700_keaf522-B172","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","volume":"132","author":"Melles","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"2026022606015088700_keaf522-B173","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026022606015088700_keaf522-B174","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/s41433-020-01380-2","article-title":"J. The Royal College of Ophthalmologists recommendations on monitoring for hydroxychloroquine and chloroquine users in the United Kingdom (2020 revision): executive summary","volume":"35","author":"Yusuf","year":"2021","journal-title":"Eye"},{"key":"2026022606015088700_keaf522-B175","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision)","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"key":"2026022606015088700_keaf522-B176","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41433-018-0136-x","article-title":"The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary","volume":"32","author":"Yusuf","year":"2018","journal-title":"Eye"},{"key":"2026022606015088700_keaf522-B177","first-page":"343","article-title":"Prevalence of hydroxychloroquine retinopathy using 2018 Royal College of Ophthalmologists diagnostic criteria","volume":"35","author":"Marshall","year":"2021","journal-title":"Eye 2020 35:1"},{"key":"2026022606015088700_keaf522-B178","first-page":"1171","article-title":"Two years\u2019 experience of screening for hydroxychloroquine retinopathy","volume":"35","author":"Gobbett","year":"2021","journal-title":"Eye 2020"},{"key":"2026022606015088700_keaf522-B179","doi-asserted-by":"crossref","first-page":"166","DOI":"10.7326\/M22-2453","article-title":"Hydroxychloroquine dose and risk for incident retinopathy","volume":"176","author":"Melles","year":"2023","journal-title":"Ann Intern Med"},{"key":"2026022606015088700_keaf522-B180","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41433-022-02159-3","article-title":"Outcomes of screening for hydroxychloroquine retinopathy at the Manchester Royal Eye Hospital: 2 years\u2019 audit","volume":"37","author":"Alieldin","year":"2023","journal-title":"Eye"},{"key":"2026022606015088700_keaf522-B181","author":"NHS England."},{"key":"2026022606015088700_keaf522-B182","author":"The Royal College of Ophthalmologists (RCOphth)","year":"2020"},{"key":"2026022606015088700_keaf522-B183","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.transproceed.2006.02.077","article-title":"Tacrolimus-associated hypomagnesemia in renal transplant recipients","volume":"38","author":"Navaneethan","year":"2006","journal-title":"Transplant Proc"},{"key":"2026022606015088700_keaf522-B184","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/ndt\/gfg515","article-title":"Hyponatraemia and hyperkalaemia are more frequent in renal transplant recipients treated with tacrolimus than with cyclosporin. Further evidence for differences between cyclosporin and tacrolimus nephrotoxicities","volume":"19","author":"Higgins","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"2026022606015088700_keaf522-B185","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/01.TP.0000174340.40585.D4","article-title":"Effects of immunosuppressive agents on magnesium metabolism early after allogeneic hematopoietic stem cell transplantation","volume":"80","author":"Aisa","year":"2005","journal-title":"Transplant"},{"key":"2026022606015088700_keaf522-B186","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3109\/0886022X.2015.1057800","article-title":"Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies","volume":"37","author":"Cheungpasitporn","year":"2015","journal-title":"Renal Failure"},{"key":"2026022606015088700_keaf522-B187"},{"key":"2026022606015088700_keaf522-B188","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.transproceed.2011.02.049","article-title":"Tacrolimus trough levels and level-to-dose ratio in stable renal transplant patients converted to a once-daily regimen","volume":"43","author":"Me\u00e7ule","year":"2011","journal-title":"Transplant Proc"},{"key":"2026022606015088700_keaf522-B189","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1097\/00007890-199912270-00003","article-title":"Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients","volume":"68","author":"Cantarovich","year":"1999","journal-title":"Transplantation"},{"key":"2026022606015088700_keaf522-B190","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/art.43212","article-title":"2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis","volume":"77","author":"Sammaritano","year":"2025","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"2026022606015088700_keaf522-B191","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.3399\/bjgp18X695465","article-title":"The epidemiology of multimorbidity in primary care: a retrospective cohort study","volume":"68","author":"Cassell","year":"2018","journal-title":"Br J Gen Pract"},{"key":"2026022606015088700_keaf522-B192","doi-asserted-by":"crossref","first-page":"101860","DOI":"10.1016\/j.eclinm.2023.101860","article-title":"Global and regional prevalence of multimorbidity in the adult population in community settings: a systematic review and meta-analysis","volume":"57","author":"Chowdhury","year":"2023","journal-title":"eClinicalMedicine"},{"key":"2026022606015088700_keaf522-B193","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrrheum.2013.212","article-title":"Multimorbidity and rheumatic conditions\u2014enhancing the concept of comorbidity","volume":"10","author":"Radner","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"2026022606015088700_keaf522-B194","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/ard.2005.043158","article-title":"Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register","volume":"65","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2026022606015088700_keaf522-B195","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1001\/jama.2024.3669","article-title":"Interstitial lung disease","volume":"331","author":"Maher","year":"2024","journal-title":"JAMA"},{"key":"2026022606015088700_keaf522-B196","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.27405","article-title":"Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study","volume":"62","author":"Bongartz","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2026022606015088700_keaf522-B197","doi-asserted-by":"crossref","first-page":"h1269","DOI":"10.1136\/bmj.h1269","article-title":"Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials","volume":"350","year":"2015","journal-title":"BMJ"},{"key":"2026022606015088700_keaf522-B198","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/art.38322","article-title":"Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials","volume":"66","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2026022606015088700_keaf522-B199","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1002\/art.41452","article-title":"Pulmonary adverse events in patients receiving low-dose methotrexate in the randomized, double-blind, placebo-controlled cardiovascular inflammation reduction trial","volume":"72","author":"Sparks","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2026022606015088700_keaf522-B200","doi-asserted-by":"crossref","first-page":"e028466","DOI":"10.1136\/bmjopen-2018-028466","article-title":"Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts","volume":"9","author":"Kiely","year":"2019","journal-title":"BMJ Open"},{"key":"2026022606015088700_keaf522-B201","doi-asserted-by":"crossref","first-page":"2000337","DOI":"10.1183\/13993003.00337-2020","article-title":"Methotrexate and rheumatoid arthritis associated interstitial lung disease","volume":"57","author":"Juge","year":"2021","journal-title":"Eur Respir J"},{"key":"2026022606015088700_keaf522-B202","doi-asserted-by":"crossref","first-page":"152561","DOI":"10.1016\/j.semarthrit.2024.152561","article-title":"Disease-modifying antirheumatic drugs and risk of incident interstitial lung disease among patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"69","author":"Zhang","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2026022606015088700_keaf522-B203","first-page":"302","article-title":"Lung function in children and adolescents with juvenile idiopathic arthritis during long-term treatment with methotrexate: a retrospective study","volume":"30","author":"Leiskau","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2026022606015088700_keaf522-B204","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1002\/ppul.26681","article-title":"Methotrexate does not affect lung function in children with juvenile idiopathic arthritis","volume":"58","author":"Perrin","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"2026022606015088700_keaf522-B205","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1136\/annrheumdis-2020-eular.2211","article-title":"THU0561 predicting liver toxicity caused by conventional synthetic disease-modifying antirheumatic drugs","volume":"79","author":"Kuusalo","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2026022606015088700_keaf522-B206","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/1756-185X.13576","article-title":"Methotrexate treatment in rheumatoid arthritis and elevated liver enzymes: a long-term follow-up of predictors, surveillance, and outcome in clinical practice","volume":"22","author":"Sundbaum","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"2026022606015088700_keaf522-B207","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.4254\/wjh.v9.i26.1092","article-title":"Risk of liver disease in methotrexate treated patients","volume":"9","author":"Conway","year":"2017","journal-title":"World J Hepatol"},{"key":"2026022606015088700_keaf522-B208","year":"2012"},{"key":"2026022606015088700_keaf522-B209","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","article-title":"Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction","volume":"64","author":"Verbeeck","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"2026022606015088700_keaf522-B210","author":"NICE","year":"2024"},{"key":"2026022606015088700_keaf522-B211","author":"NHS England"},{"key":"2026022606015088700_keaf522-B212","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1532-5415.1985.tb07117.x","article-title":"Longitudinal studies on the rate of decline in renal function with age","volume":"33","author":"Lindeman","year":"1985","journal-title":"J Am Geriatr Soc"},{"key":"2026022606015088700_keaf522-B213","author":"NICE","year":"2021"},{"key":"2026022606015088700_keaf522-B214","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/acr.23014","article-title":"Secular changes in clinical features at presentation of rheumatoid arthritis: increase in comorbidity but improved inflammatory states","volume":"69","author":"Nikiphorou","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2026022606015088700_keaf522-B215","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrrheum.2011.75","article-title":"Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE","volume":"7","author":"Symmons","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"2026022606015088700_keaf522-B216","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","article-title":"Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease","volume":"108","author":"Micha","year":"2011","journal-title":"Am J Cardiol"},{"key":"2026022606015088700_keaf522-B217","doi-asserted-by":"crossref","first-page":"R151","DOI":"10.1186\/ar2045","article-title":"Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study","volume":"8","author":"van Halm","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"2026022606015088700_keaf522-B218","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","article-title":"EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome","volume":"81","author":"Drosos","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026022606015088700_keaf522-B219","author":"NICE","year":"2020"},{"key":"2026022606015088700_keaf522-B220","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"New Engl J Med"},{"key":"2026022606015088700_keaf522-B221","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis.","volume":"386","author":"Ytterberg SR, Bhatt DL, Mikuls TR et al.","year":"2022","journal-title":"New Engl J Med"},{"key":"2026022606015088700_keaf522-B222","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2026022606015088700_keaf522-B223","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1067\/mjd.2002.125579","article-title":"Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management","volume":"47","author":"Berg","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"2026022606015088700_keaf522-B224","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA"},{"key":"2026022606015088700_keaf522-B225","doi-asserted-by":"crossref","first-page":"101698","DOI":"10.1016\/j.trim.2022.101698","article-title":"Higher mycophenolate dosage is associated with an increased risk of squamous cell carcinoma in kidney transplant recipients","volume":"75","author":"Shao","year":"2022","journal-title":"Transplant Immunology"},{"key":"2026022606015088700_keaf522-B226","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ajo.2008.04.035","article-title":"Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence","volume":"146","author":"Kempen","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"2026022606015088700_keaf522-B227","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/aje\/kws375","article-title":"Use of azathioprine and the risk of cancer in inflammatory bowel disease","volume":"177","author":"Pasternak","year":"2013","journal-title":"Am J Epidemiol"},{"key":"2026022606015088700_keaf522-B228","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.chest.2021.12.636","article-title":"Malignancy risk associated with mycophenolate mofetil or azathioprine in patients with fibrotic interstitial lung disease","volume":"161","author":"Lok","year":"2022","journal-title":"CHEST"},{"key":"2026022606015088700_keaf522-B229","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/rheumatology\/kep376","article-title":"Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-\u03b1 blockers: perioperative interruption of tumour necrosis factor-\u03b1 blockers decreases complications?","volume":"49","author":"Kawakami","year":"2010","journal-title":"Rheumatology"},{"key":"2026022606015088700_keaf522-B230","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1136\/ard.2005.037762","article-title":"Surgery in patients receiving anti-tumour necrosis factor \u03b1 treatment in rheumatoid arthritis: an observational study on 50 surgical procedures","volume":"64","author":"Wendling","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2026022606015088700_keaf522-B231","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/ard.60.3.214","article-title":"Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery","volume":"60","author":"Grennan","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"2026022606015088700_keaf522-B232","first-page":"1129","article-title":"Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis","volume":"20","author":"Sany","year":"1993","journal-title":"J Rheumatol"},{"key":"2026022606015088700_keaf522-B233","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/01.RHU.0000062514.54375.bd","article-title":"Examination of the risk of continuous leflunomide treatment on the incidence of infectious complications after joint arthroplasty in patients with rheumatoid arthritis","volume":"9","author":"Tanaka","year":"2003","journal-title":"J Clin Rheumatol"},{"key":"2026022606015088700_keaf522-B234","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3109\/s10165-005-0444-4","article-title":"Lack of increase in postoperative complications with low-dose methotrexate therapy in patients with rheumatoid arthritis undergoing elective orthopedic surgery","volume":"16","author":"Murata","year":"2006","journal-title":"Modern Rheumatol"},{"key":"2026022606015088700_keaf522-B235","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1053\/jhsu.2002.32958","article-title":"Influence of steroids and methotrexate on wound complications after elective rheumatoid hand and wrist surgery","volume":"27","author":"Jain","year":"2002","journal-title":"J Hand Surg"},{"key":"2026022606015088700_keaf522-B236","first-page":"823","article-title":"Methotrexate and post operative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery\u2014a ten year follow-up","volume":"77","author":"Sreekumar","year":"2011","journal-title":"Acta Orthop Belg"},{"key":"2026022606015088700_keaf522-B237","first-page":"1844","article-title":"Risk factors for early wound complications after orthopedic surgery for rheumatoid arthritis","volume":"22","author":"Escalante","year":"1995","journal-title":"J Rheumatol"},{"key":"2026022606015088700_keaf522-B238","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/imj.16073","article-title":"Australian recommendations on perioperative use of disease-modifying anti-rheumatic drugs in people with inflammatory arthritis undergoing elective surgery","volume":"53","author":"Buchbinder","year":"2023","journal-title":"Intern Med J"},{"key":"2026022606015088700_keaf522-B239","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/acr.24893","article-title":"2022 American College of Rheumatology\/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty","volume":"74","author":"Goodman","year":"2022","journal-title":"Arthritis Care Res"},{"key":"2026022606015088700_keaf522-B240","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1001\/archsurg.138.3.314","article-title":"A.f.S. Risk factors for postoperative infectious complications in noncolorectal abdominal surgery","volume":"138","author":"Pessaux","year":"2003","journal-title":"Arch Surg"},{"key":"2026022606015088700_keaf522-B241","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/art.509","article-title":"Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2026022606015088700_keaf522-B242","doi-asserted-by":"crossref","first-page":"152099","DOI":"10.1016\/j.semarthrit.2022.152099","article-title":"Predictors of infection requiring hospitalization in patients with systemic lupus erythematosus: a time-to-event analysis","volume":"57","author":"Ko","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2026022606015088700_keaf522-B243","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/ard.2010.128637","article-title":"High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis","volume":"70","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2026022606015088700_keaf522-B244","doi-asserted-by":"crossref","first-page":"R139","DOI":"10.1186\/ar3453","article-title":"The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses","volume":"13","author":"Dixon","year":"2011","journal-title":"Arthritis Research & Therapy"},{"key":"2026022606015088700_keaf522-B245","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1002\/art.34530","article-title":"Development and validation of a risk score for serious infections in patients with rheumatoid arthritis","volume":"64","author":"Crowson","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2026022606015088700_keaf522-B246","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/art.39070","article-title":"Serious infections among adult medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis","volume":"67","author":"Feldman","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2026022606015088700_keaf522-B247","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1177\/0961203318811598","article-title":"Infections in newly diagnosed Spanish patients with systemic lupus erythematosus: data from the RELES cohort","volume":"27","author":"Gonz\u00e1lez-Echavarri","year":"2018","journal-title":"Lupus"},{"key":"2026022606015088700_keaf522-B248","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12916-016-0673-8","article-title":"Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis","volume":"14","author":"Singh","year":"2016","journal-title":"BMC Medicine"},{"key":"2026022606015088700_keaf522-B249","article-title":"Methotrexate for treating rheumatoid arthritis","volume":"2014","author":"Lopez-Olivo","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2026022606015088700_keaf522-B250","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/jcm8010015","article-title":"Risk of infection with methotrexate therapy in inflammatory diseases: a systematic review and meta-analysis","volume":"8","author":"Ibrahim","year":"2018","journal-title":"J Clin Med"},{"key":"2026022606015088700_keaf522-B251","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/rheumatology\/kem076","article-title":"Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis","volume":"46","author":"Bernatsky","year":"2007","journal-title":"Rheumatology"},{"key":"2026022606015088700_keaf522-B252","first-page":"1182","article-title":"Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis","volume":"30","author":"Osiri","year":"2003","journal-title":"J Rheumatol"},{"key":"2026022606015088700_keaf522-B253","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000510","article-title":"Infection hospitalisation in systemic lupus in Sweden","volume":"8","author":"Simard","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2026022606015088700_keaf522-B254","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s40744-023-00595-5","article-title":"Association between mycophenolate mofetil use and subsequent infections among hospitalized patients with systemic lupus erythematosus: a nested case\u2013control study","volume":"10","author":"Guo","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2026022606015088700_keaf522-B255","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.2165\/11319260-000000000-00000","article-title":"Immunosuppressive drugs in kidney transplantation","volume":"69","author":"Marc\u00e9n","year":"2009","journal-title":"Drugs"},{"key":"2026022606015088700_keaf522-B256","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.3390\/ph6101170","article-title":"Safety of immunosuppressive drugs used as maintenance therapy in kidney transplantation: a systematic review and meta-analysis","volume":"6","author":"Almeida","year":"2013","journal-title":"Pharmaceuticals"},{"key":"2026022606015088700_keaf522-B257","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/acr.22035","article-title":"Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review","volume":"65","author":"Pego-Reigosa","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2026022606015088700_keaf522-B258","author":"National Institute for Health and Care Excellence. Rheumatoid arthritis in adults: management (NICE Guideline No. NG100)."},{"key":"2026022606015088700_keaf522-B259"},{"key":"2026022606015088700_keaf522-B260","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1093\/rheumatology\/keab917","article-title":"Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study","volume":"61","author":"Sherbini","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026022606015088700_keaf522-B261","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1136\/ard.2008.106617","article-title":"Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study","volume":"69","author":"Verstappen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2026022606015088700_keaf522-B262","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10067-012-2136-8","article-title":"Risk of alanine transferase (ALT) elevation in patients with rheumatoid arthritis treated with methotrexate in a DAS-steered strategy","volume":"32","author":"Dirven","year":"2013","journal-title":"Clin Rheumatol"},{"key":"2026022606015088700_keaf522-B263","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2217\/ijr.12.57","article-title":"Prediction of response and adverse events to methotrexate treatment in patients with rheumatoid arthritis","volume":"7","author":"Verstappen","year":"2012","journal-title":"Int J Clin Rheumatol"},{"key":"2026022606015088700_keaf522-B264","doi-asserted-by":"crossref","first-page":"e2345132","DOI":"10.1001\/jamanetworkopen.2023.45132","article-title":"Low-dose methotrexate and serious adverse events among older adults with chronic kidney disease","volume":"6","author":"Muanda","year":"2023","journal-title":"JAMA Network Open"},{"key":"2026022606015088700_keaf522-B265","doi-asserted-by":"crossref","first-page":"e0154744","DOI":"10.1371\/journal.pone.0154744","article-title":"Factors associated with myelosuppression related to low-dose methotrexate therapy for inflammatory rheumatic diseases","volume":"11","author":"Mori","year":"2016","journal-title":"PLoS One"},{"key":"2026022606015088700_keaf522-B266","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1093\/rheumatology\/keab304","article-title":"Prevalence and predictors of adverse events with methotrexate mono-and combination-therapy for rheumatoid arthritis: a systematic review","volume":"60","author":"Sherbini","year":"2021","journal-title":"Rheumatology"},{"key":"2026022606015088700_keaf522-B267","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1093\/rheumatology\/keab790","article-title":"Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum","volume":"61","author":"Nakafero","year":"2022","journal-title":"Rheumatology"},{"key":"2026022606015088700_keaf522-B268","doi-asserted-by":"crossref","first-page":"e003980","DOI":"10.1136\/rmdopen-2023-003980","article-title":"Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation","volume":"10","author":"Abhishek","year":"2024","journal-title":"RMD Open"},{"key":"2026022606015088700_keaf522-B269","doi-asserted-by":"crossref","first-page":"102213","DOI":"10.1016\/j.eclinm.2023.102213","article-title":"Risk-stratified monitoring for thiopurine toxicity in immune-mediated inflammatory diseases: prognostic model development, validation, and, health economic evaluation","volume":"64","author":"Nakafero","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2026022606015088700_keaf522-B270","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1546-0096-12-51","article-title":"Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review","volume":"12","author":"van Dijkhuizen","year":"2014","journal-title":"Pediatr Rheumatol"},{"key":"2026022606015088700_keaf522-B271","doi-asserted-by":"crossref","first-page":"e074678","DOI":"10.1136\/bmj-2022-074678","article-title":"Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK","volume":"381","author":"Nakafero","year":"2023","journal-title":"BMJ"},{"key":"2026022606015088700_keaf522-B272","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis","volume":"343","author":"Bathon","year":"2000","journal-title":"New Engl J Med"},{"key":"2026022606015088700_keaf522-B273","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/art.41384","article-title":"Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator\u2013controlled trial","volume":"72","author":"van Vollenhoven","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2026022606015088700_keaf522-B274","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.semarthrit.2015.05.003","article-title":"Risk of liver injury among methotrexate users: a meta-analysis of randomised controlled trials","volume":"45","author":"Conway","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2026022606015088700_keaf522-B275","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/ard.2004.023408","article-title":"Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities","volume":"64","author":"Yazici","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2026022606015088700_keaf522-B276","first-page":"1727","article-title":"Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis","volume":"31","author":"Kent","year":"2004","journal-title":"J Rheumatol"},{"key":"2026022606015088700_keaf522-B277","first-page":"517","article-title":"Methotrexate use in rheumatoid arthritis is associated with few clinically significant liver function test abnormalities","volume":"23","author":"Yazici","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2026022606015088700_keaf522-B278","doi-asserted-by":"crossref","first-page":"e000739","DOI":"10.1136\/rmdopen-2018-000739","article-title":"Neutropaenia in early rheumatoid arthritis: frequency, predicting factors, natural history and outcome","volume":"4","author":"Fragoulis","year":"2018","journal-title":"RMD Open"},{"key":"2026022606015088700_keaf522-B279","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/rheumatology\/keh685","article-title":"Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 years","volume":"44","author":"Lim","year":"2005","journal-title":"Rheumatology"},{"key":"2026022606015088700_keaf522-B280","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","article-title":"2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features","volume":"63","author":"Beukelman","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2026022606015088700_keaf522-B281","volume-title":"Disease-Modifying Antirheumatic Drugs (DMARDs) in children with Juvenile Idiopathic Arthritis (JIA)","author":"Kemper","year":"2011"},{"key":"2026022606015088700_keaf522-B282","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12969-018-0255-8","article-title":"Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting","volume":"16","author":"Ferrara","year":"2018","journal-title":"Pediatric Rheumatology"},{"key":"2026022606015088700_keaf522-B283","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/adc.88.3.197","article-title":"Use of methotrexate in juvenile idiopathic arthritis","volume":"88","author":"Ramanan","year":"2003","journal-title":"Arch Dis Childhood"},{"key":"2026022606015088700_keaf522-B284","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12882-017-0553-2","article-title":"Renal association clinical practice guideline in post-operative care in the kidney transplant recipient","volume":"18","author":"Baker","year":"2017","journal-title":"BMC Nephrol"},{"key":"2026022606015088700_keaf522-B285","author":"Kidney Disease Improving Global Outcomes (KDIGO)"},{"key":"2026022606015088700_keaf522-B286","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3899\/jrheum.191008","article-title":"Long-term safety and effectiveness of tacrolimus in patients with lupus nephritis: 5-year interim postmarketing surveillance study in Japan (TRUST)","volume":"48","author":"Takeuchi","year":"2021","journal-title":"J Rheumatol"},{"key":"2026022606015088700_keaf522-B287","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"key":"2026022606015088700_keaf522-B288","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/rheumatology\/keae175","article-title":"Patient and health professional views on risk-stratified monitoring of immune-suppressing treatment in adults with inflammatory diseases","volume":"64","author":"Fuller","year":"2025","journal-title":"Rheumatology"},{"key":"2026022606015088700_keaf522-B289","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1093\/rheumatology\/keab254","article-title":"What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline?","volume":"60","author":"Nakafero","year":"2021","journal-title":"Rheumatology"},{"key":"2026022606015088700_keaf522-B290","doi-asserted-by":"crossref","first-page":"rkac046","DOI":"10.1093\/rap\/rkac046","article-title":"Incidence and pattern of mycophenolate discontinuation associated with abnormal monitoring blood-test results: cohort study using data from the Clinical Practice Research Datalink Aurum","volume":"6","author":"Nakafero","year":"2022","journal-title":"Rheumatol Adv Pract"},{"key":"2026022606015088700_keaf522-B291","first-page":"1521","article-title":"Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial","volume":"31","author":"Kremer","year":"2004","journal-title":"J Rheumatol"},{"key":"2026022606015088700_keaf522-B292","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1016\/S2665-9913(22)00028-5","article-title":"Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA): a double-blind, placebo-controlled, randomised, trial","volume":"4","author":"Mulder","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2026022606015088700_keaf522-B293","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/ard.2008.101378","article-title":"Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and\/or leflunomide","volume":"69","author":"Curtis","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2026022606015088700_keaf522-B294","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jhep.2020.06.007","article-title":"Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease","volume":"73","author":"Hagstr\u00f6m","year":"2020","journal-title":"J Hepatol"},{"key":"2026022606015088700_keaf522-B295","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"New Engl J Med"},{"key":"2026022606015088700_keaf522-B296","author":"NHS England"},{"key":"2026022606015088700_keaf522-B297","author":"NICE","year":"2023"},{"key":"2026022606015088700_keaf522-B298","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3399\/bjgp16X685177","article-title":"Good practice in shared care for inflammatory arthritis","volume":"66","author":"Lythgoe","year":"2016","journal-title":"Br J Gen Pract"},{"key":"2026022606015088700_keaf522-B299","author":"National Patient Safety Agency","year":"2006"},{"key":"2026022606015088700_keaf522-B300","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.3399\/bjgp20X710993","article-title":"Trends and variation in unsafe prescribing of methotrexate: a cohort study in English NHS primary care","volume":"70","author":"MacKenna","year":"2020","journal-title":"Br J Gen Pract"},{"key":"2026022606015088700_keaf522-B301","author":"NHS England"},{"key":"2026022606015088700_keaf522-B302","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s12026-014-8564-6","article-title":"Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity?","volume":"60","author":"Rom\u00e3o","year":"2014","journal-title":"Immunol Res"},{"key":"2026022606015088700_keaf522-B303","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1445-5994.2009.02059.x","article-title":"Lack of association between elevated mean red cell volume and haematological toxicity in patients receiving long-term methotrexate for rheumatoid arthritis","volume":"40","author":"White","year":"2010","journal-title":"Intern Med J"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf522\/65287126\/keaf522.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/2\/keaf522\/65287126\/keaf522.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/2\/keaf522\/65287126\/keaf522.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T11:02:31Z","timestamp":1772103751000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keaf522\/8322743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":303,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf522","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,11,14]]},"article-number":"keaf522"}}